You just read:

Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimer's Disease From Merck

News provided by

Acumen Pharmaceuticals, Inc.

21 Dec, 2011, 13:00 GMT